[{"indications": "Indications\u00a0type 2 diabetes mellitus (as monotherapy or in combination with metformin\r\nwhen metformin alone inadequate)", "name": "REPAGLINIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs"], "cautions": "Cautions\u00a0substitute insulin during intercurrent\r\nillness (such as myocardial infarction, coma, infection,\r\nand trauma) and during surgery (omit repaglinide on morning of surgery\r\nand recommence when eating and drinking normally); debilitated\r\nand malnourished patients; interactions: Appendix 1 (antidiabetics)", "side-effects": "Side-effects\u00a0abdominal pain, diarrhoea, constipation, nausea,\r\nvomiting; rarely hypoglycaemia, hypersensitivity\r\nreactions including pruritus, rashes, vasculitis, urticaria, and visual\r\ndisturbances", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/73892.htm", "doses": ["adult over 18 years, initially\r\n500\u00a0micrograms within 30 minutes before main meals (1\u00a0mg if transferring\r\nfrom another oral hypoglycaemic), adjusted according to response at\r\nintervals of 1\u20132 weeks; up to 4\u00a0mg may be given as a single dose,\r\nmax. 16\u00a0mg daily; elderly over 75 years,\r\nnot recommended"], "pregnancy": "Pregnancy\u00a0avoid"}]